Last reviewed · How we verify
GemDOx
At a glance
| Generic name | GemDOx |
|---|---|
| Sponsor | Cooperative Study Group A for Hematology |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of Effectiveness of GEMDOX in Relapsed Osteosarcoma
- Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GemDOx CI brief — competitive landscape report
- GemDOx updates RSS · CI watch RSS
- Cooperative Study Group A for Hematology portfolio CI